Endurance Wealth Management’s Outlook Therapeutics OTLK Stock Holding History

Endurance Wealth Management’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$35K	Buy	1,000 +500	+100%	+$13.6K	﹤0.01%	378
2023 Q1	$11K	Buy	+500	New	+$11.2K	﹤0.01%	495
2022 Q3	–	Sell	-750	Closed	-$15K	–	633
2022 Q2	$15K	Hold	750	–	–	﹤0.01%	447
2022 Q1	$27K	Hold	750	–	–	﹤0.01%	416
2021 Q4	$20K	Hold	750	–	–	﹤0.01%	441
2021 Q3	$33K	Buy	+750	New	+$36.2K	﹤0.01%	394

Other funds holding OTLK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

LNC

Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return

Endurance Wealth Management's OTLK Position: Q2 2023 in Review

Endurance Wealth Management increased its Outlook Therapeutics (OTLK) stake by 100% in Q2 2023, buying an estimated $13.6K and bringing the position to 1,000 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #378.

Endurance Wealth Management first reported a position in OTLK in Q3 2021 and has held it in 6 quarters since. 87 funds tracked by Wall St. Rank hold OTLK as of Q2 2023.

Endurance Wealth Management held 1,000 shares of Outlook Therapeutics worth $35K as of Q2 2023.
Endurance Wealth Management bought 500 Outlook Therapeutics shares in Q2 2023, an estimated $13.6K.
Outlook Therapeutics made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #378 holding.
Endurance Wealth Management first reported a position in Outlook Therapeutics in Q3 2021 and has held it in 6 quarters since.
87 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.